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Abstract 
Pharmacokinetic interactions between natural products and conventional drugs can adversely impact patient 
outcomes. These complex interactions present unique challenges that require clear communication to researchers. 
We are creating a public information portal to facilitate researchers’ access to credible evidence about these 
interactions. As part of a user-centered design process, three types of intended researchers were surveyed: drug-
drug interaction scientists, clinical pharmacists, and drug compendium editors. Of the 23 invited researchers, 17 
completed the survey. The researchers suggested a number of specific requirements for a natural product-drug 
interaction information resource, including specific information about a given interaction, the potential to cause 
adverse effects, and the clinical importance. Results were used to develop user personas that provided the 
development team with a concise and memorable way to represent information needs of the three main researcher 
types and a common basis for communicating the design’s rationale.   
Introduction 
Concomitant use of conventional (prescription and non-prescription) drugs and natural products (NPs)—including 
vitamins, minerals, herbal medicinal products, and other botanicals—is a frequent occurrence. Approximately 50% 
of Americans in their midlife are exposed to prescription drugs simultaneously with an NP,1 raising concerns for 
NP-drug interactions (NPDIs). A 2012 overview of systematic reviews of herbal medicinal products identified 81 
interactions between 35 of these NPs and 31 drug classes.2 Several interactions resulted in adverse outcomes, 
including transplant rejection, cardiovascular collapse, renal and liver toxicity, and death. Estimating the prevalence 
of potential NPDIs is difficult because patient use is often underreported and unstructured in health records.3,4 One 
study reported ~34% of patients 
prescribed warfarin were 
exposed to an NP that conferred 
a significant risk for an adverse 
interaction.5 Often, it is difficult 
for researchers to answer 
important questions about a 
purported NPDI, such as 
mechanisms and potential 
clinical impact, either due to a 
lack of evidence or to 
variability among evidence 
sources.  
To provide evidence-based 
information about purported 
NPDIs, the National Center for 
Complementary and Integrative 
Health (NCCIH) established a 
new Center of Excellence for 
Natural Product Drug Interaction Research (NaPDI Center) (U54 AT008909). The NaPDI Center has an 
Figure 1. The NaPDI Center’s publicly accessible database. 
PK, pharmacokinetic; PBPK, physiologically-based PK 
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Administrative Core, which coordinates the efforts of three scientific cores:  Analytical, Pharmacology, and 
Informatics (Figure 1). The Informatics Core focuses on creating a 
publicly accessible database where researchers can access raw data, 
summarized scientific results, and recommended approaches to 
optimally assess the clinical significance of pharmacokinetic NPDIs. 
Prior experience with an existing proprietary repository of human in 
vitro and clinical drug-drug interaction (DDI) data6 informed the 
initial design of a new publicly accessible database for NPDI studies. 
The Informatics Core works with the Analytical and Pharmacology 
Cores to gather, organize, and archive various types of data that are 
generated prospectively (Figure 1). In parallel, the Informatics Core is 
extending the Potential Drug-drug Interaction and Potential Drug-drug 
Interaction Evidence Ontology (DIDEO)7,8 to provide a semantically-
rich resource from which a common set of data elements for the 
database can be derived. 
One of the NaPDI Center’s goals is to make its analytical, in vitro and 
in vivo (clinical) data accessible to researchers. Toward that goal, the 
Center is developing a public portal intended to serve a diverse group 
of researchers interested in assessing NPDIs. Potential users include, 
but are not limited to: 
• scientists interested in gaining mechanistic understanding of 
interactions between conventional medication and natural 
products;  
• clinical pharmacists interested in pharmacodynamics, 
pharmacokinetics, pharmacogenomics, metabolomics, etc. as they 
relate to drug exposure, response, and interactions; and  
• drug information compendium editors  interested in developing 
narratives that summarize NPDIs for clinical audiences and for use as clinical decision support tools. 
The portal should provide a reliable resource where researchers can access raw data, summarized scientific results, 
and recommended approaches for investigating NPDIs. To meet these requirements, it is important to first 
understand what information researchers need to make informed decisions about these NPDIs. Specifically,  
• What type of information regarding NPDIs do researchers need?  
• How do researchers perceive the structure of existing NPDI resources? 
• How do researchers perceive the information available on existing NPDI resources? 
• Who are the hypothetical users for a NPDI database, and how will they use this database? 
This conference paper describes a user information needs survey that was used to improve the understanding of 
these questions. Results inform the user-centered design process that we are employing for the public portal design 
(Figure 2). 
Materials and Methods  
Participants and Setting  
We developed a new user-needs survey designed to gain a better understanding of researchers’ NPDI information 
needs and their perceptions of the resources and websites affiliated with these NPDIs. Survey design was a 
collaborative effort of the Informatics Core team members. Members of the Informatics Core provided input, 
examples, models, and literature in support of best practices for designing questionnaires when creating user 
personas and use cases. The initial user-needs survey was pre-tested with seven people who including researchers, 
clinical pharmacists, and compendia editors. The Washington State University Institutional Review Board provided 
expedited approval for this survey.  
 
Figure 2. The user-centered design workflow 
being used to develop a publicly accessible 
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Survey responses were used to create general user 
profiles (personas) for the user-centered design of a web-
based information portal for the NaPDI Center. The 
survey also informed navigation, site credibility, and 
workflow process best geared toward the generation of a 
positive and useful user experience. The pre-test 
participants were excluded from data analysis.  
The final and revised survey was delivered via 
Qualtrics®, an internet-based research service. Research 
scientists, clinical pharmacists, and content editors from 
various organizations and universities were asked to 
participate in the study. This purposive sample consisted 
of 23 total participants (12 women and 11 men). They 
were selected based on their specific roles and areas of 
expertise to represent a diversity of needs and 
perspectives associated with NPDI and DDI research. 
Data were collected from March 20, 2017 to April 21, 
2017. Participants completed the survey at venues of their 
choice; they were not compensated for their time. 
Participants took approximately 10 minutes to complete 
the survey consisting of 16 questions. They completed the 
survey anonymously but self-identified by their areas of expertise (Table 1). Participants could choose more than 
one area of expertise. 
Measures and Procedure  
Participants provided 11 responses regarding their knowledge of DDI resources (e.g., “In relation to these web-
based resources, how unfamiliar or familiar are you with drug interaction sections in FDA product labels?”). 
Table 2. General information needs relevant to natural product-drug interactions 
Information Need N = 17 total Example Quote 
Category 1: Drug and Interaction Information 
Pharmacokinetics (PK) 13 “Include references if a drug interaction between the natural product 
and the drug may also occur at the pharmacodynamic level (agonist 
and antagonist effect).” - DDI Scientist 
 
“For PK, we like to have area under the curve (AUC) change at 
therapeutic concentrations that are also connected to a PD 
effect/result.” - Clinical Pharmacist  
 
“I like to have the name of the product used in a study and most 
importantly, if it is standardized to a certain amount of % of active 
component.” - Drug Compendium Editor 
Mechanism of action 9 
Pharmacodynamics (PD) 5 
Dosage 5 
Relevance to time 2 
Interaction role 1 
Drug product 1 
Category 2: Adverse Effects 
Overlapping effects 2 “Time of onset, likelihood of overlapping effects, and potential 
additive nature of side effects.” - Clinical Pharmacist  
Frequency of adverse 
effects 1 
Likelihood of an adverse 
effect 1 
Category 3: Seriousness 
Clinical importance 17 
“Do the results translate to a clinically relevant outcome?” - DDI 
Scientist  
 
Table 1. User information needs and seeking behavior 
questionnaire participant demographics 
Number of participants  (N = 17 total) 
Area(s) of Expertise1 
DDI scientist 11 
Clinical pharmacist 8 
Drug compendium editor 4 
Bioanalytical research scientist 3 
Systems analyst or content specialist 2 
Physician 1 
Other health care provider 1 
Toxicologist 1 
Public health researcher 1 
1Because participants may have identified themselves as 
having multiple areas of expertise, the total number of 
areas of expertise was 32. 
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Responses were measured on a four-point Likert-type scale, from “very unfamiliar” to “very familiar,” coded 0 to 3, 
respectively. In addition to this scale, participants had a “no opinion” option. 
Participants supplied 26 responses regarding perceived importance of drug interaction website capabilities (e.g., 
“How unimportant or important do you find news sections highlighting new publications on natural product-drug 
interactions?”). Responses were measured on a four-point Likert-type scale, from “very unimportant” to “very 
important,” coded 0 to 3, respectively. In addition to this scale, participants had a “no opinion” option. 
Open-ended questions allowed participants to elaborate on their information-seeking needs and behaviors (e.g., 
“What information is most important when looking at potential NPDI or DDI resources?”). Data from open-ended 
questions were coded using the qualitative data analysis system NVivo. Two research assistants conducted open and 
axial coding for a total of 106 response paragraphs to identify emergent themes.9 This process included the reading 
and rereading of participants’ responses for familiarization, identification, and organization of the text into codes. 
Then, two additional research assistants verified the coding and analysis; they subsequently arranged quotes to 
answer the proposed research questions. 
Results  
A total of 23 participants received and began the survey; 17 of the 23 (73.9%) participants completed the survey in 
its entirety. Results include responses for the 17 completed cases. Table 1 provides frequencies for participants’ 
responses, in which participants were asked to “check all that apply.” Researchers self-identified with ten of 13 
discrete areas of expertise. None of the participants chose the following expertise options: “analytical chemist,” 
“regulatory scientist,” and “none of the above.” Four participants wrote in additional areas of expertise, which 
Table 3. Researcher requirements for a natural product-drug interaction information resource 
Requirement N = 17 total Example Quote 
Structure of the Resource 
Links to other 
resources 3 “I'm not exactly sure what all is included in the NaPDI Recommended 
Approaches, but I think case reports can also be important. In my 
experience, the amount of information about a potential interaction 
involving a natural product is often limited, and therefore, any and all 
information can be valuable in such cases.” - Drug Compendium Editor 
Case studies 2 
Detailed 
summaries 2 
Recommendations  1 
Perception of the Resource 
Professional 
organization 11 
“Authenticity and transparency of the websites (well established by known 
organizations, agencies or universities, and supervised by known experts in 
the field). Frequency of the website's updates of content to keep the 
information provided the most accurate as possible based on the present 
knowledge on the field.” - DDI Scientist 
 
“It's nice to have links to references embedded within the interaction text so 
the reader can determine exactly which text came from a specific reference.” 





Regularly updated 3 
Perception of the Information 
Inclusion of human 
data  8 “Are the results generated from in vitro, in silico, in vivo (animal model), or 
in vivo (human) methods?” - DDI Scientist 
 
“Quantitative information about the interaction.” - Clinical Pharmacist 
Inclusion of result 
magnitude 5 
Quantitative data 2 
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included “computational chemistry,” “pharmacogenetics,” “psychiatric pharmacy” and “quantitative clinical 
pharmacology.” A majority of participants identified as DDI scientists, clinical pharmacists, or drug compendium 
editors (Table 1). As such, the data analysis contains three sections that address the research practices, information 
needs, resource requirements, and resource evaluations for each group.  
Three themes emerged based on participants’ discussions of information needs. These themes included drug 
interaction information, information related to adverse interaction effects, and information concerning the clinical 
importance of interactions. A summary of these results and representative quotes are provided in Table 2.  
General Resource and Information Evaluation  
Participants were interested in resources that provide links to outside sources, with a specific focus on academic 
references to literature, case studies, and available data. A majority of participants noted the importance of an NPDI 
database being created, reviewed, monitored, and updated by DDI scientists and other credible sources. Across all 
groups, an NPDI database was noted as a useful and a desired tool. Participants stated that they are often frustrated 
with the lack of credible NPDI information available. Results suggest that perceptions of information in an NPDI 
database would be positively influenced through the inclusion of human data, reporting of interaction result 
magnitude, presence of clinical trials, and quantitative data. A summary of these results and representative quotes 
are provided in Table 3.  
User Personas 
User Persona 1: DDI Scientist 
A majority of surveyed DDI scientists were familiar with drug information search and retrieval methods.  These 
methods included searching MEDLINE using Medical Subject Heading (MeSH) terms, guidelines from the U.S. 
Food and Drug Administration, European Medicines Agency, and other regulatory agencies for evaluating clinical 
drug interactions and methodologies for in vitro and clinical evaluation of drug interactions. When using NPDI 
databases, participants cited the importance of the overall clinical relevance of study results, whether or not the 
NPDI study results can be extrapolated to other NPs, and background information and literature on potential NPDIs. 
One participant noted the desire for information on the purity and accuracy of NP constituents and potential 
contaminants. DDI scientists requested a systematic database of NPDIs that fits into the larger drug interaction 
research framework. Interaction information also should contain detailed records of pharmacodynamic interactions, 
such as coagulation parameters and product information. The most important resource attribute noted by DDI 
scientists was a site’s search capability. Participants also desired links to contact an expert or related researcher, a 
glossary for the search, and a news section that highlights new publications on pharmacokinetic NPDIs.   
Table 4. User Persona 1 - Jessica, DDI Scientist 
Tasks Jessica is a DDI scientist who spends 24 hours per week researching NPDIs or DDIs and 8 




Jessica selects three areas of interaction information in a pharmacokinetic NPDI database that 
she considers to be very important. These included quantitative clinical parameters measuring 
the risk/extent of NPDIs and DDIs, mechanistic understanding of NPDIs and DDIs, and the 
rationale and validation for the NPDI or DDI studies. Jessica selects five categories of important 
background information to include in a pharmacokinetic NPDI database: (1) background 
information of the NP and its constituents, such as clinical use and sales data; (2) chemical 
structure of and physicochemical information on NP constituents, such as molecular weight or 
log P value; (3) whether or not the NPDI study results can be extrapolated to other NPs; (4) 
overall clinical relevance; and (5) evaluation framework information. 
Information 
Seeking 
Jessica states that she currently uses information from interaction websites as a guide point. She 
is cautious about pharmacokinetic NPDI information because “much of the data reported is 
often fraught with methodological flaws.”  Jessica states that there are issues with analyzing 
pharmacokinetic NPDIs that make the interactions more difficult to research than DDIs. As 
such, Jessica is interested in the study design of research in the database, including whether or 
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PubMed was noted as the top indexed, scientific literature resource on which DDI scientists spend time. The prime 
subscription-based databases with drugs and NP interaction information were Lexicomp® and Micromedex®. The 
most cited open-access databases with interaction information were PharmGKB, ClinicalTrials.gov, and 
Drugs@FDA. Additionally, DDI scientists stated that they use the web resource from the NCCIH. As such, these 
researchers had varying knowledge of NPDIs. They also reported spending 2 to 40 hours (median 7 hours) per week 
researching NPDIs or DDIs, and 1 to 40 hours (median 5 hours) per week on related research websites  
User Persona 2: Clinical Pharmacist 
A majority of surveyed clinical pharmacists were very familiar with drug interaction sections in FDA product labels. 
Similar to DDI scientists, they often used drug information search and retrieval methods and were very familiar with 
methodologies for in vitro and clinical evaluation of drug interactions.  
When using NPDI databases, quantitative clinical parameters measuring the risk/extent of NPDIs was of highest 
importance. In addition, clinical pharmacists were interested in the mechanistic understanding of NPDIs and the 
rationale and validation for the NPDI or DDI studies. As with the DDI scientists, all clinical pharmacists noted the 
importance of an NPDI database featuring overall clinical relevance of study results. A majority of participants with 
this expertise were also interested in whether or not the NPDI studies’ results with a probe drug can be extrapolated 
to other drugs and other NPs. Clinical pharmacists requested a database that offers case studies and information 
summaries. In line with DDI scientists’ needs, clinical pharmacists noted the need for interaction information with 
detailed records of pharmacokinetic and pharmacodynamic interactions. One clinical pharmacist cited the need for 
understanding consequences when NPs are affected by drugs, rather than just viewing NPs as precipitants. As with 
DDI scientists, the most important resource attribute noted by clinical pharmacists was a website’s search capability. 
Participants also desired links to contact an expert or related researcher. Unlike DDI scientists, clinical pharmacists 
noted the importance of a discussion section on an NPDI database.  
PubMed and Google Scholar were noted as the top indexed scientific literature resources on which participants 
spend time. The prime subscription-based databases with drugs and NP interaction information were Lexicomp® 
and Micromedex®. The most cited databases with interaction information were the University of Washington’s 
Drug Interaction Database (DIDB), PharmGKB, Drugs@FDA, Indiana University P450 Drug Interaction Table, 
Natural Standard Integrated Medicine, PubChem, and NCCIH. The clinical pharmacists reported spending less time 
researching NPDIs than DDI scientists, but more time on websites containing clinical, research, or drug information. 
The clinical pharmacists reported spending 0 to 40 hours (median 2 hours) per week researching NPDIs or DDIs and 
1 to 30 hours (median 4 hours) per week on related research websites  
 
Table 5. User Persona 2 - Carl, Clinical Pharmacist 
Tasks Carl is a clinical pharmacist who spends 2-3 hours per week researching NPDIs or DDIs and 
one hour per week on related websites.  
Information 
Needs 
Carl selects four areas of interaction information in a pharmacokinetic NPDI database that he 
sees as highly important. These include the quantitative clinical parameters measuring the 
risk/extent of NPDIs, mechanistic understanding of NPDIs and DDIs, the bioanalytical 
methodology used for NPDI studies, and the rationale and validation for the NPDI or DDI 
studies. Carl also requests information pertaining to the “overlapping physiologic reactions with 
the target patient population.” 
 
Carl selects four categories of important background information to include in a NPDI database: 
(1) whether or not the NPDI study results can be extrapolated to other NPs, (2) whether or not 
the NPDI study results with a probe drug can be extrapolated to other drugs, (3) overall clinical 
relevance, and (4) documentation. 
Information 
Seeking 
Carl would like a NPDI database to include a search option, search glossary, and news sections 
highlighting new publications on NPDIs. Carl believes the ideal website would allow for him to 
analyze if a certain NP will interact with a patient's current or prospective drugs or medical 
condition. Carl states that the level of risk and clinical relevance are important factors to 
consider. He notes the prominence of quality research that addresses problems with NPs, such 
as “the presence of multiple ingredients in the products, and concern for the lack of GMP 
quality of these products or adulteration with prescription medications or other supplements.” 
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User Persona 3: Drug Compendium Editor 
All of the surveyed drug compendium editors were very familiar with drug interaction sections in FDA product 
labels. A majority of participants were very familiar with guidelines for evaluating clinical drug interactions and 
methodologies for in vitro and clinical evaluation of drug interactions. A majority of participants were very familiar 
with the evaluation of mechanisms of action of bioactive constituents in NPs and drug information search and 
retrieval methods. When using NPDI databases, quantitative clinical parameters measuring the risk/extent of NPDIs 
were of top importance. Drug compendium editors, like clinical pharmacists, were interested in the mechanistic 
understanding of NPDIs and the rationale and validation for NPDI or DDI studies. The two main preferences for 
information resources were overall clinical relevance of study results and whether or not the NPDI study results with 
a probe drug could be extrapolated to other drugs. The most important resource attributes noted by drug 
compendium editors were a site’s search capability and acknowledgement of research sponsorship, endorsements, or 
funding.  
All drug compendium editors surveyed reported using PubMed as their top indexed scientific literature resource and 
Drugs@FDA for interaction information. Drug compendium editors used interaction information to provide 
clinicians with DDI guidance, crosscheck information for various drugs, and to update current databases with NPDI 
and DDI information. Drug compendium editors reported spending 1 to 20 hours (median 2 hours) per week 
researching NPDIs or DDIs and 20 to 30 hours (median 30 hours) per week on websites related to interactions. 
Discussion 
The researchers who participated in this study reported needing detailed, systematic, and updated information 
regarding NPDI information. Such information includes but is not limited to the nature of the interaction 
(pharmacokinetic or pharmacodynamic), mechanism of the interaction, and likelihood that exposed patients will 
experience specific adverse effects. Participants emphasized the importance of putting NPDIs and DDIs into a larger 
drug interaction research framework, such as comparing new findings to existing research. Researchers from any of 
the three expertise areas used to create personas suggested that clinical relevance of the NPDI interaction 
information in a NPDI database is the most important attribute of this type of resource.  
Quality and Content  
 Our results suggest that participants are interested in a website that offers quantitative data and detailed summaries 
of NPDIs. For purposes of credibility, participants noted the importance of including human data and citations to 
studies that support any findings. Generally, participants indicated interest in the full range of relevant study 
information, including whether or not study results can be extrapolated to other NPs or other drugs. Additional 
Table 6. User Persona 3 - Joe, Drug Compendium Editor 
Tasks Joe is a drug compendium editor who rarely conducts research on NPDIs or DDIs, but he spends 
an average of 30 hours per week on websites containing clinical, research, or drug information. 




Joe selects four areas of interaction information in an NPDI database as very important: 
quantitative clinical parameters measuring the risk/extent of pharmacokinetic NPDIs, 
mechanistic understanding of NPDIs and DDIs, the bioanalytical methodology used in NPDI 
studies, bioanalytical characterization of NPs, and the rationale and validation for the NPDI or 
DDI studies. Additionally, Joe stated, “I like to have the name of the NP used in a study and 
most importantly, if it is standardized to a certain amount or % of active component.”  
 
Joe selects five categories of important background information to include in an NPDI database: 
(1) whether or not the NPDI study results can be extrapolated to other NPs, (2) whether or not 
the NPDI study results with a probe drug can be extrapolated to other drugs, (3) overall clinical 




Joe believes an incisive data source would include percent change in pharmacokinetic 
parameters, clinical relevance (e.g., loss of effectiveness, increase in adverse effects), and the 
mechanism of the effect. Joe desires database attributes that include search capability, recent 
news, and documentation of funding. 
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information needs include background information of the NP and its constituents, such as clinical use and sales data.  
Participants also were interested in the chemical structure of and physicochemical information of NP constituents.   
User Personas 
User personas have been a useful tool in user-centered design since Alan Cooper reported their use in goal-directed 
design nearly 20 years ago.10 They form an important complement to other user-centered activities such as 
contextual inquiry and think-aloud usability studies.11 Personas are a useful tool to focus project development on the 
needs of hypothetical users. Defining potential users by their characteristics, potential behaviors, and potential 
experiences through persona development provides a focused approach in concept development. Successful use of 
user-centered design with personas include personal health record tools, developing an electronic care plan for 
individuals with chronic kidney disease, informing the design of a communicable disease information systems to 
improve public health.12–14  
Their importance to the NaPDI Center’s public portal and data repository is two-fold: 1) provide a concise and 
memorable way to represent distinct aspects of the three main researcher types, and 2) provide a common basis for 
communicating the rationale for the portal design. The three personas we created are grounded in the data collected 
from the survey and show important differences between the researcher types across the categories of work tasks, 
information needs, and information seeking behavior. Each persona will serve as a conduit of information about a 
specific user type that we will modify as the user-centered design process advances. We will define the initial user 
experience design for the portal by reflecting on the personas and related information needs. For example, the user 
experience should include an advanced search page that provides a simple interface for finding studies and 
experiments information based on the information needs reported in each user personas (Tables 3-5).  
Related Data Repositories 
A variety of NPDI reviews have been published in the scientific literature.2,15,16 The Natural Medicines™ database17, 
developed by the Therapeutic Research Center, claims to provide comprehensive information regarding NPs 
including uses in treating specific conditions and comparative effectiveness. The database provides a screening tool 
for possible NPDIs that is oriented to clinicians and does not provide detailed data about the original studies. The 
Global Natural Products Social Molecular Networking  web site18 provides the Mass Spectrometry Interactive 
Virtual Environment (MassIVE) data repository to enable researchers to analyze and compare Mass Spectrometry 
datasets. The National Cancer Institute’s Office of Cancer Complementary and Alternative Medicine (OCCAM), 
whose primary focus on cancer outcomes, provides descriptions called Physician Data Query (PDQ®) on topics that 
include complementary and alternative medicine.19 Some of the PDQs provide general information on NPDIs 
written for a clinical or patient audience.  
Limitations  
The present study has limitations. The first and perhaps most important limitation is the small, convenience sample. 
Additionally, qualitative data analysis is subject to data interpretation bias. To help ameliorate this bias, data in the 
present study were independently analyzed and verified by two groups of research assistants. When discrepancies in 
coding occurred, they were discussed and re-coded based on group consensus. 
Conclusion 
Americans frequently combine conventional drugs with NPs. As such, there is a need for researchers to have access 
to credible research and information regarding the risk or safety of NPDIs. The present study analyzed the opinions 
and information needs of three types of NPDI researchers: DDI scientists, clinical pharmacists, and drug 
compendium editors. Results will inform the user-centered design of a public information portal that will provide 
raw data, summarized scientific results, and recommended approaches for the rigorous study of pharmacokinetic 
NPDIs.  This information will facilitate researchers’ access for evidence-based decisions regarding these NPDIs. 
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